Nefopam is a non-opioid analgesic used to treat moderate pain, especially when weaker painkillers like paracetamol or NSAIDs are ineffective. It is commonly prescribed for:
• Postoperative pain
• Dental pain
• Joint and muscle pain
• Cancer-related pain
• Chronic pain conditions
Nefopam works by inhibiting the reuptake of serotonin, dopamine, and norepinephrine, affecting pain transmission in the central nervous system. It does not belong to the NSAID or opioid class and does not cause respiratory depression. Nefopam is available only by prescription in many countries.
Parent: Nefopam
Impurities in Nefopam may arise during synthesis, formulation, or storage. Regulatory guidelines from agencies like the FDA, EMA, and ICH specify impurity thresholds to ensure product safety, efficacy, and stability.
Process-Related Impurities
• Unreacted intermediates in phenylamine or benzoxazocine synthesis
• Residual solvents such as ethanol, methanol, or chloroform
• Synthetic by-products from ring closure and alkylation steps
Degradation Impurities
• Oxidation by-products from air or light exposure
• Hydrolysis products in humid conditions
• Heat-induced degradation compounds
Elemental Impurities
• Heavy metals (e.g., lead, cadmium, arsenic, mercury) from catalysts or processing equipment
Analytical Techniques for Impurity Detection
• High-Performance Liquid Chromatography (HPLC)
• Gas Chromatography (GC)
• Fourier-Transform Infrared Spectroscopy (FT-IR)
• Mass Spectrometry (MS)
• Nefopam is considered a moderate-strength painkiller.
• It is stronger than paracetamol or ibuprofen, but weaker than opioids like morphine.
• It’s often used when NSAIDs or mild analgesics are not sufficient, but opioids are not yet necessary.
• It is especially useful because it does not cause drowsiness or respiratory depression like opioids.
• Nefopam is not banned in most countries, but its use is restricted or not approved in some regions due to:
o Side effects, including nausea, dizziness, confusion, and hallucinations
o Limited clinical trial data compared to other analgesics
o Potential for misuse, though it is non-opioid
• In some countries, alternative pain management options are preferred due to regulatory or safety concerns.
• Tramadol is generally considered stronger than Nefopam, as it has opioid activity in addition to serotonin/norepinephrine reuptake inhibition.
• However, Nefopam has the advantage of avoiding opioid-related side effects, such as dependence and respiratory depression.
• The choice between the two depends on pain severity, patient history, and side effect profile.
• Nefopam typically relieves pain without causing sedation.
• Some users report mild stimulation, dizziness, or euphoria, especially at higher doses.
• Possible side effects include:
o Nausea
o Dry mouth
o Sweating
o Insomnia or nervousness
• Rarely, it can cause hallucinations or confusion, particularly in elderly patients or those sensitive to CNS effects.
